Twice daily ceftriaxone therapy for serious bacterial infections in children

Tasnee Chonmaitree, Blaise L. Congeni, Jose Munoz, Tamara A. Rakusan, Keith R. Powell, Quellin T. Box

    Research output: Contribution to journalArticlepeer-review

    6 Scopus citations


    The clinical efficacy and safety of ceftriaxone, a long half-life cephalosporin were evaluated in 48 children with a variety of serious bacterial infections. Clinical cure was achieved in 92% (44 of 48) of patients. Peak serum bactericidal titres for Haemophilus influenzae type b, Streptococcus pneumoniae, Str. pyogenes and Escherichia coli were ≧ 1 :1024. Mean peak and trough ceftriaxone levels were 173 and 42 mg/1, respectively. Mild and transient diarrhoea was observed in 10% of patients. Laboratory side effects encountered were eosinophilia, thrombocytosis and neutropenia in another 8%. Ceftriaxone is a useful antibiotic for common childhood infections. Its prolonged half-life allows twice daily administration which reduces problems related to intravenous therapy as well as the cost and personnel time.

    Original languageEnglish (US)
    Pages (from-to)511-516
    Number of pages6
    JournalJournal of Antimicrobial Chemotherapy
    Issue number5
    StatePublished - May 1984

    ASJC Scopus subject areas

    • Pharmacology
    • Microbiology (medical)
    • Infectious Diseases
    • Pharmacology (medical)


    Dive into the research topics of 'Twice daily ceftriaxone therapy for serious bacterial infections in children'. Together they form a unique fingerprint.

    Cite this